A clinical result is not yet an investment case. For nearly four decades, Burns McClellan has worked in the narrow, consequential gap between the laboratory and the capital markets.
Scale sells something executives rarely admit they need: a second mind in the room when every sentence carries consequences. Its founders learned the trade in politics, professional tennis, Fortune 500 boardrooms and one of corporate history's loudest failed IPOs.
Biotech has no shortage of science. It has a shortage of attention at exactly the moment attention becomes money. astr partners built a referral-only advisory firm around that bottleneck.